Under the agreement, Itochu Chemical Frontier (ICF) will supply injectable products for which Sagent will obtain the US regulatory approval and market them in the US.
Jeffrey Yordon, CEO, founder and chairman of the board of Sagent Pharmaceuticals, said: “Sagent is committed to expanding its network of worldwide strategic partnerships to offer diverse and extensive pipeline of the injectable products to our hospital-focused customers and we look forward to including ICF amongst our partners.”
Jun Sato, ICF’s president and CEO, said: “ICF looks forward to rapidly expanding our presence in the US market. We believe that this collaboration combining ICF’s experience in the Japanese market with Sagent’s US focused injectable selling and marketing capabilities is an optimal path toward achieving this objective.”